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Background: There is still signiﬁcant risk of patients developing surgical site infection (SSI) following
orthopaedic surgery due to growing demand for joint surgery in high-risk patients and increasing
complexity of procedures. The higher rate of SSI seen in high-risk procedures and also in high-risk
patients is of concern as the development of infection can be a very serious complication of ortho-
paedic surgery and has implications for patient morbidity, length of hospital stay (LOS), resource uti-
lisation and healthcare costs. This article provides an overview of the efﬁcacy of prophylactic and
therapeutic application of resorbable gentamicin-containing collagen implants (GCCI) in the prevention
of SSI following orthopaedic surgical procedures.
Method: Thirteen publications were identiﬁed using the PubMed online database and search terms
‘gentamicin-containing collagen implant’ plus ‘orthopaedic surgery’, ‘osteomyelitis’, ‘osteitis’, ‘amputa-
tion’, ‘surgical site infection’ and ‘wound infection’.
Results: Five studies have demonstrated that prophylactic use of GCCI can reduce the wound infection
rate in orthopaedic surgical procedures ranging from discectomy to amputation in patients with dia-
betes. Eight studies have demonstrated that GCCI may also have a role to play in treating both acute and
chronic osteomyelitis.
Conclusion: This review demonstrates that prophylactic use of GCCI can have a positive effect on wound
healing in a range of orthopaedic surgical procedures and in high-risk patients. GCCI may also have a role
to play in the treatment of osteomyelitis.
 2012 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Recently published statistics may give the impression that the
risk of developing a surgical site infection (SSI) following ortho-
paedic surgery is both low and diminishing.1 In routine orthopaedic
procedures such as knee and total hip arthroplasty the risk of
developing SSI is relatively low compared to other areas such as
colon surgery. For example in total hip arthroplasty the risk of
patients developing SSI is less than 2% compared to 10% after small
bowel surgery.1,2 In 2010 the UK Health Protection Agency (HPA)
reported a drop in the rate of SSI following hip hemiarthroplasty
from 4.6% in 2004/2005 to 2.4% in 2007/2008.1 However, these
statistics portray only part of the picture and the occurrence of SSI
is an area for concern in orthopaedic surgery due to the emergence
of several key trends.
The risk of developing SSI is relatively low in procedures such as
knee and total hip arthroplasty (<2%), however, the absolute2402.
en.de
ciates Ltd. Published by Elsevier Ltnumber of SSI is increasing due to a growing number of elderly
patients with osteoarthritis requiring joint replacement surgery.1,3
Birrell and colleagues forecast that there would be a 40% increase
in the need for hip replacement surgery in the UK between 1996
and 2026 due to demographic change alone.4 In 2009/10 the
National Joint Registry (NJR) in the UK reported a growth of 19% in
the number of primary hip replacements performed in the ﬁve
years since 2005/06 (71,021 vs 59,648).3
Orthopaedic procedures are also being performed in a growing
number of patients with co-morbid conditions such as diabetes
mellitus and in increasingly elderly patients, both of which are
factors known to increase the risk of SSI.1,3,5 Data reported by the
UK HPA between 2008 and 2010 highlighted a two-fold increase in
the SSI rate in patients aged 85 years or over (1.3%) compared to
that in patients aged 65e74 years (0.6%) undergoing hip arthro-
plasty.1 Furthermore the SSI rate in high-risk patients (National
Nosocomial Infections Surveillance [NNIS] risk index 2 and 3)
undergoing the same procedure is more than three times as great
as that in low-risk patients (NNIS risk index 0) i.e. 1.9% and 0.5%
respectively.1 In 2003 the NJR reported that 9% of hip replacementsd. All rights reserved.
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(ASA) grade 3 patients (grade 3¼ incapacitating systemic disease).3
By 2010 the proportion of procedures carried out in this risk cate-
gory had risen to 13%.3
The risk of SSI in orthopaedic surgery is also increasing due to
the complexity and length of surgery together with the use of
prosthetic implants which are known risk factors for infection.3,5 It
has been demonstrated that bacteria around prosthetic implants
may form a ‘bioﬁlm’, which in turn provides protection against the
immune system and antibiotics.6,7 The rate of SSI is also higher in
hip and knee revisions compared to primary procedures. In knee
revisions the SSI rate is 3.6%, more than double the rate for
a primary knee procedure (1.6%).8
The higher rate of SSI seen in high-risk procedures and also in
high-risk patients is of concern as the development of infection can
be a very serious complication of orthopaedic surgery and has
implications for patient morbidity, length of hospital stay (LOS),
resource utilisation and healthcare costs. In the UK concern over SSI
following orthopaedic surgery has resulted in mandatory surveil-
lance being put in place.9 If systemic antibiotic prophylaxis fails to
prevent infection, the treatment of infection is challenging, particu-
larly in joint replacement where the removal of the implant may be
required.7 The presence of SSI in patients undergoing joint replace-
mentsmay double the time spent recovering in hospital compared to
those patients without SSI.8 In patients undergoing primary knee
arthroplasty the average LOShasbeen estimatedat ninedays in those
patientswithout SSI compared to 18 days in thosewith an infection.8
In patients undergoing revision of knee arthroplasty the presence of
SSI can increase the average LOS from 12 to 24 days.8
A further complication speciﬁc to orthopaedic surgery is the
development of osteomyelitis, which is difﬁcult to treat and
successful eradication of infection usually requires surgical inter-
vention and long-term high-dose antibiotics.10 If the acute stage is
not treated successfully chronic osteomyelitis may develop and this
form of the condition tends to persist regardless of its initial cause
and despite aggressive treatment.11
The development of SSI following orthopaedic surgery has
serious implications for patients, healthcare professionals and
health authorities. Therefore there is a need for effective means of
preventing SSI especially in high-risk procedures and patient
groups in order to improve patient morbidity and decrease
healthcare costs.
The mainstay of SSI prevention in addition to strict aseptic
surgical technique is the use of antibiotic prophylaxis administered
systemically both pre- and post-operatively.5 However, long-term
administration of systemic antibiotics periods may lead to a risk
of antibiotic resistance and toxicity.
The development of technologies such as resorbable
gentamicin-containing collagen implant (GCCI), which deliver high
local concentrations of gentamicin with corresponding low serum
levels offer a means of
- reducing SSI rate following orthopaedic surgery and treating
osteomyelitis12,13
- lowering the risk of antibiotic resistance by reducing the need
for long-term administration of systemic antibiotics14,15
- avoiding toxicity associated with systemic antibiotics16
- avoiding the need for re-operation as the implant is fully
resorbable17
The use of collagen as a carrier also has positive effects on
wound healing.17
Of particular relevance in orthopaedic surgery is that systemic
antibiotics are often ineffective against the bacteria within the
‘bioﬁlm’ associatedwith implant infection.7 GCCI can deliver higherlevels of local antibiotics required to eradicate the ‘bioﬁlm’.7 In an
in vitro study by Pons group GCCI were used to eradicate bacterial
colonisation by Staphylococcus aureus of a range of biomaterials
including stainless steel screws, titanium screws, titanium canu-
lated screws and a cylinder of polyethylene.18 After one week of
incubation all samples were free of bacteria.18
GCCI also have an advantage in the treatment of osteomyelitis as
unlike some other antibiotics, which have a detrimental effect on
osteoblasts, aminioglycosides such as gentamicin appear to have
a neutral effect. This has important implications for orthopaedic
surgery.10
A number of resorbable GCCI are available worldwide. The
object of this article is to review published clinical data for
prophylactic and therapeutic application of resorbable GCCI in
orthopaedic surgery in order to provide an overview of the efﬁcacy
and safety of GCCI in this area.
2. Methods
In order to identify candidate publications a literature search was conducted
using the National Institutes of Health PubMed database for articles published
between January 1990 and July 2011. Articles were identiﬁed using the search terms
‘gentamicin-containing collagen implant’ plus ‘orthopaedic surgery’, ‘osteomyelitis’,
‘osteitis’, ‘amputation’, ‘surgical site infection’ and ‘wound infection’. Reference lists
of recent review articles were also scanned for additional citations. The literature
search was further supplemented by abstracts from international Orthopaedic
Surgery congresses, which took place between January 2009 and July 2011. Review
publications were excluded from the analysis. The search identiﬁed 13 potential
publications focusing speciﬁcally on the prophylaxis and treatment of SSI in
orthopaedic surgery. These studies concerned the use of two GCCI i.e. Collatamp
(EUSA Pharma [Europe], Oxford, United Kingdom) and an unspeciﬁed implant.
Collatamp contains gentamicin sulphate at a rate of 2 mg/cm.2 The collagen in
Collatamp is present at 2.8 mg/cm2 and is type I collagen from a renatured bovine or
equine source.
The outcome measures of primary interest were SSI rate; wound healing rate;
time to wound healing together with post-operative complication rate. Other
outcome measures for the ‘treatment’ studies included rate of osteomyelitis relapse
and functional recovery. The level of evidence for each study was graded according
to the criteria developed by Carruthers et al.19
3. Clinical experience
To date 13 clinical studies have been published, which have
focused on the local application of gentamicin-containing collagen
implants (GCCI) in the prophylaxis and treatment of SSI in ortho-
paedic surgery (Table 1). Five studies utilised GCCI on a prophylactic
basis, three of which were inwhat would be considered procedures
at high risk of developing SSI. One of the ‘prophylactic’ studies was
of randomised, controlled design [Level 1]; three included patient
series with contemporaneous or historical controls and one
included a patient series without any type of control group.
In eight additional studies GCCI were used to treat existing acute
or chronic osteomyelitis (Table 1). One of the ‘treatment’ studies
was of randomised, controlled design [Level 1]; two included
patient series with contemporaneous or historical controls and ﬁve
included patient series without any type of control group. The 13
studies represent experience in 1561 patients with GCCI (n ¼ 1531




There is a growing body of data to support the use of GCCI in
high-risk groups undergoing orthopaedic surgical procedures in
reducing wound infection rates and wound healing time. Three
studies have focused speciﬁcally on the use of GCCI followingmajor
and minor amputations in patients with diabetes or diabetes
complications.
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patients requiring revision of failed below the knee amputation
stumps [Level 4].21 The indication for primary amputation consisted
of a mixture of vascular insufﬁciency, diabetic gangrene, both
vascular insufﬁciency and diabetic gangrene or osteomyelitis. All of
the patients in the GCCI group (n¼ 8) healed satisfactorily, although
one required revision of the scar six months later. In the group of
historical controls two out of the seven stumps healed after split skin
grafting and ﬁve were converted to above the knee amputations.
Varga and colleagues undertook a randomised study in which
50 patients with diabetes underwent minor amputations [Level
1].12 Patients were randomised to application of GCCI (Group I) or to
no adjunctive treatment (Group II) (Table 1).12 Patients in Group I
had signiﬁcantly shorter wound healing time compared to those in
Group II (p < 0.05). Group I patients healed on average 13 days
quicker than those in Group II. Although there was a trend towards
a lower re-amputation rate in Group I the difference between the
two groups was not signiﬁcant.
In a further study by Varga’s group in patients with diabetes
undergoing metatarsophalangeal resection use of GCCI was
compared to no adjunctive treatment [Level 3].22 Therewas a trend
towards a shorter time to wound healing in the GCCI group,
however, the difference between the two groups was not signiﬁ-
cant. There was also no signiﬁcant difference between the two
groups in the rate of re-amputation.
3.1.2. Repair of open fractures
In a case series report of 35 patients presenting with open frac-
tures (6 h post injury) the efﬁcacy of immediate plate osteosyn-
thesis and GCCI (þ3e5 days systemic antibiotics) were used with
the aim of promoting wound and bone healing [Level 5].23 When
patients were assessed at 40 weeks post-surgery the majority of
fractures were considered to have united within an acceptable time
frame. Local wound complications were reported in three out of 31
of patients (9.7%) and deep infection in two out of 31 patients (6.5%).
None of the patients with deep wound infection required implant
removal and both fractures healed in time. In ﬁve out of 31 patients
(16.1%) delayed union was noted. No patient progressed to non-
union or implant failure during long-term follow-up.
3.1.3. Spinal surgery
The prophylactic use of GCCI has also been assessed inprocedures
where patients are at lower risk of developing SSI e.g. lumbar dis-
cectomy. In a large study of 1642 patients the ﬁrst 508 patients
received no prophylactic antibiotics and the following 1134 patients
had GCCI placed in the cleared disc space prior to wound closure
[Level 4].20 None of the patients in whom GCCI was applied became
symptomatic compared to 3.7% of the historical controls who
developed post-operative spondylodiscitis (p < 0.00001). The
patientswhodevelopedspondylodiscitiswere treatedwith28daysof
clindamycin duringwhich the CRP and ESR returned to normal levels.
3.2. Treatment
3.2.1. Acute and chronic osteomyelitis
The efﬁcacy of GCCI has been compared to that of polymer
polymethylmethacrylate (PMMA) beads in the treatment of chronic
osteomyelitis in three studies. PMMA beads require re-operation at
a later date to remove them as they are not resorbed.7 The ﬁrst
randomised, prospective study compared two groups of 10 patients
each with osteomyelitis of the long bones [Level 2].13 Pharmaco-
kinetic analysis demonstrated that gentamicinwas rapidly released
from the implant (sponge) leading to high levels in wound exudate
and urine within the ﬁrst 48 h with measurable but non-toxic
concentrations in serum. By comparison the release of gentamicinfrom the beads was much slower. Despite the differences seen in
the release characteristics between the two groups there was no
difference seen between the infection rates in both groups with all
infectious parameters eradicated in 80e90% of patients at follow-
up. However, the number of re-operations was signiﬁcantly
higher in the group treated with PMMA beads.
In a second larger study of 108 patients with chronic sclerosing
osteomyelitis the use of GCCI was compared on a prospective basis
to use of PMMA beads in conjunction with a standardised
debridement protocol [Level 3].30 Patients were followed up for
a mean of 6.1 years (3.8e9.3). The patients treated with the PMMA
beads were three timesmore likely to require re-operationwithin 3
months due to persistent infection compared to those treated with
GCCI (p ¼ 0.0001).
A third study compared GCCI (plus an arthroscopic procedure)
with PMMA beads (an open procedure and placement of a wound
drain) in shoulder surgery [Level 4].29 The patients in the GCCI and
closed procedure group had an earlier convalescence and improved
clinical outcome compared to the PMMAbeads plus openprocedure
group. The duration of post-operative treatment was reduced by 16
days in the GCCI group compared to that in the PMMA bead group.
Several case series reports have also reported similar levels of
infection resolution as seen in the Letsch study when GCCI were
used to treat both acute and chronic osteomyelitis [Level 5].24e28
The osteomyelitis was reported at a wide range of sites; however,
the majority of infections were present in the leg bones. The
osteomyelitis was of mixed aetiology i.e. post-traumatic, post-
operative etc. Staphylococcus aureus was the most common caus-
ative microorganism found in wound secretions across the studies.
Complete resolution of osteomyelitis infection was reported in the
majority of cases.4. Discussion
SSIs following orthopaedic surgery have signiﬁcant impact on
patient morbidity and resource utilisation and therefore there is
a need for more effective prevention in high-risk patients and
procedures. Prolonged use of systemic antibiotics can lead to
antibiotic resistance and side effects. The adjunctive use of GCCI
avoids the risks of systemic antibiotic administration by delivering
high local concentrations of gentamicin with corresponding low
serum levels.
This review has demonstrated that prophylactic use of GCCI can
signiﬁcantly decrease the development of spondylodiscitis in
patients undergoing low-risk procedures such as lumbar dis-
cectomy. However, more importantly GCCI can help to improve
wound healing in higher-risk procedures such as amputation in
patients with diabetes. Prophylactic use of GCCI has also been
shown to positively inﬂuence the post-operative course for patients
undergoing revision of failed below the knee amputation. These
results have positive implications for patients, surgeons and local
health economies as amputation in patients with diabetes carries
with it one of the highest risks of SSI.2
Patients with chronic osteomyelitis often face the prospect of
multiple surgical procedures and long-term antibiotics to eradicate
infection. The use of GCCI would seem to have an advantage over
use of PMMA beads in the treatment of osteomyelitis by avoiding
the need for re-operation. GCCI have also been shown to eradicate
osteomyelitis of mixed aetiology when used in conjunction with
surgical debridement in a high percentage of patients. GCCI may
also lead to shorter convalescence time in patients with
osteomyelitis.
Few adverse side effects associated with GCCI were reported in
the reviewed studies.
Table 1
Overview of GCCI clinical publications in orthopaedic surgery.














n ¼ 1642 total patients,
n ¼ 1712 total discectomies
Group I: n ¼ 1134
gentamicin-collagen implant
(1064 operations for 1089
primary disc herniations & 109
re-operations for recurrent
lumbar disc herniations)
Group II: n ¼ 508 control e no
prophylactic antibiotics (479
operations for 495 primary disc
herniations & 60 re-operations
for recurrent lumbar disc
herniations)
Spondylodiscitis: Group I:
0% (0/1134) vs Group II: 3.7%
(19/508) (p < 0.00001)
Amputation







n ¼ 62 total of which n ¼ 12
failed to heal




Group II: n ¼ 7 control
Wound healing: Group I:
8/8 vs Group II: 2/7






n ¼ 50 total patients
Group I: n ¼ 25
gentamicin-collagen
implant
Group II: n ¼ 25
control e no treatment
Re-amputation rate: Group I:
6/25 vs Group II: 8/25 (n.s.)
Wound healing: Group I:
21 days (range 12e120) vs
Group II: 34 days
(range 18e140) median time
to wound healing (p < 0.05)






n ¼ 41 total patients, n ¼ 47
total amputations
Group I: n ¼ 14 patients
(n ¼ 15 amputations)
gentamicin-collagen implant
Group II: n ¼ 27 patients
(n ¼ 32 amputations) control
Time to complete wound
healing: Group I: 21 days vs
Group II: 28 days (n.s.)
Repair of open fractures





n ¼ 35 total patients with
gentamicin-collagen implant
n ¼ 31 patients followed-up
At follow-up (mean 40 weeks)
local wound complications
found in 3/31 patients. Deep
infection was found in 2/31
patients e these fractures
united in due course. Delayed
union was noted in 5/31patients.
No patients relapsed in the
long-term. Excessive scarring
was noted in 6.5% (2/31)
patients.
Treatment




defect ﬁlled with a mixture
of spongy bone and one





n ¼ 64 total patients treated
with gentamicin-collagen
implant
n ¼ 59 patients followed-up
Osteitis: 50/59 of patients had
healed and 4/59 of patients
relapsed at one year follow-up
Ascherl (1990)25 Collatamp
One (dry) 10 cm  10 cm
implant was placed loosely
into the infected cavity





n ¼ 54 total
n ¼ 14 post-traumatic OM; n ¼ 11
post-operative OM; n ¼ 2
hematogenic OM; n ¼ 27 septic
prosthesis loosening
All treated with gentamicin-collagen
implant alone
Chronic osteomyelitis: 40/54of




ﬁstulas and affected bone
tissue the implant was




n ¼ 10 treated with
gentamicin-collagen
implant þ systemic antibiotics
Chronic osteomyelitis: All
patients had resolution of
osteomyelitis at one year
post-operatively
Wernet (1992)27 Collatamp Case series report
Chronic
osteomyelitis
n ¼ 47 patients treated with
gentamicin-collagen implant
Osteomyelitis: 44/47 had
alleviation of infection. 3
patients had persistent ﬁstula.
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Table 1 (continued )
Author Product Design & population Number of subjects and treatment
groups
Results







n ¼ 20 total patients
Group I: n ¼ 10 gentamicin-collagen
implant
Group II: n ¼ 10 PMMA beads
Release characteristics: Group I:
Local levels of 1400 mg/l at 6 h
post-insertion & non-therapeutic
levels in plasma vs Group II:
Local levels of 100 mg/l at 3 h
post-insertion.
Osteomyelitis: Group I: 80%




number of re-operations was
signiﬁcantly lower in group I
(1.1) vs group II (1.9)





n ¼ 90 total
n ¼ 49 osteitis
n ¼ 41 soft-tissue infection
All treated with gentamicin-collagen
implant
Wound healing: 39/41 of
patients with soft-tissue
infections achieved primary
wound healing. 45/49 of
patients with osteitis had
successful suppression of infection





n ¼ 46 total
Group I: n ¼ 25 gentamicin-collagen
implant þ arthroscopic procedure
Group II: n ¼ 21 open
procedure þ wound drain
Time to convalescence: Group I
had an earlier convalescence and
improved clinical outcome
compared to Group II
Duration of post-operative
treatment: Group I had
post-operative treatment for
33 days compared to 49 days
in Group II




n ¼ 108 total
Group I: n ¼ 54 gentamicin-collagen
implant
Group II: n ¼ 54 PMMA beads
Re-operation: Group I: 11/54 vs
Group II: 36/54 (p ¼ 0.0001).
There was no difference noted
between the groups for CRP
(p ¼ 0.46), ESR (p ¼ 0.09), WBC
(p ¼ 0.24) & local wound healing
criteria (p ¼ 0.34)
a Also known as Collatamp EG, Collatamp Cronocol, Duracoll Implant, Garacol, Garacoll, Garacoll Implant, Garamacin Pads, Garamycin, Garamycin
Schwamm, Gentacoll, Gentacoll Implant, Gentalyn, Gentimplant, Sulmycin, Sulmycin Implant E Schwamm, Sulmycin Implant Schwamm.
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and cardio-thoracic surgery where GCCI have been proven to
prevent SSI in a range of procedures and patient groups.16,31 GCCI
have been used in surgery for over 25 years with rare reports of
implant-related adverse events.16
Further, randomised controlled studies are needed in high-risk
patients and in high-risk orthopaedic procedures to explore the
impact of GCCI on length of hospital stay, requirement for re-
operation, patient quality of life, post-operative course and func-
tional recovery and also to conﬁrm the ﬁndings of the reviewed
studies. Studies are also required to evaluate the health economic
beneﬁt of GCCI in orthopaedic surgery.5. Conclusions
This review demonstrates that prophylactic use of GCCI can have
a positive effect on wound healing in a range of orthopaedic
surgical procedures and in high-risk patients. GCCI may also have
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